CORRECTED-MARKET PULSE-Ariad Pharmaceuticals

Fri Nov 22, 2013 9:15am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

(Corrects to say the European agency backed continued use of the drug, not that it recommended first approval)

Nov 22 (Reuters) -

** ARIAD PHARMACEUTICALS INC, Thursday close $2.79, up 25 pct premarket

The company said European regulators recommended the continued use of its leukemia drug, Iclusig, whose U.S. sale has been suspended due to safety concerns. (Compiled by Natalie Grover; Editing by Sriraj Kalluvila)